^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
CANCER:

Eye Cancer

Related cancers:
1d
Metastases from uveal melanoma may lack S100 expression: A clinico-pathologic and immunohistochemical study with emphasis on potential causes and diagnostic implications. (PubMed, Ann Diagn Pathol)
The absence of S100 in metastatic UM may reflect a shift in antigenic expression, possibly due to tumor dedifferentiation or clonal selection of S100-negative cells with a higher metastatic potential. Our findings emphasize the importance of employing a comprehensive immunohistochemical panel, including markers such as HMB45, SOX10, and Melan-A, in the accurate diagnosis of metastatic melanomas.
Journal
|
SOX10 (SRY-Box 10) • MLANA (Melan-A)
5d
ISITE: Investigation of Somatic Alterations in Tumours of the Eye (clinicaltrials.gov)
P=N/A, N=92, Enrolling by invitation, The Wellcome Sanger Institute
New trial
5d
Uveal melanoma and its local inflammation - good or bad for the patient? (PubMed, Vestn Oftalmol)
Monitoring microRNA-155 expression levels in the plasma of UM patients may help predict occult metastasis prior to enucleation. This is not only crucial for clinical follow-up but may also play a significant role in the development of targeted therapies.
Journal
|
MIR155 (MicroRNA 155)
5d
Plant cell-cycle regulators control the nuclear environment for viral pathogenesis. (PubMed, Cell Host Microbe)
The improper disruption of RBR1-E2F complexes via hijacking APC/CCDC20 causes the host growth repression. We uncover a scenario in which the virus co-opts host APC/CCDC20 to reprogram RBR1-E2F complex to favor its propagation while dampening host vitality.
Journal
|
CCND1 (Cyclin D1) • CDC20 (Cell Division Cycle 20)
6d
Exploring the metabolic alterations in cervical cancer induced by HPV oncoproteins: From mechanisms to therapeutic targets. (PubMed, Biochim Biophys Acta Rev Cancer)
This review summarizes the role of HPV oncoproteins in metabolic reprogramming and their contributions to the development and progression of cervical cancer. Additionally, this review provides insights into how metabolic reprogramming opens avenues for novel therapeutic strategies, including the discovery of new and repurposed drugs that could be applied to treat cervical cancer.
Review • Journal
|
MYC (V-myc avian myelocytomatosis viral oncogene homolog) • HIF1A (Hypoxia inducible factor 1, alpha subunit)
7d
RBBP8 Is a Prognostic Biomarker Associated With Response to Immune Checkpoint Inhibitors in Advanced Gastric Cancer. (PubMed, J Immunother)
The HG and LG showed no significant difference in the number of TIICs; however, there was a difference in the number ratios of CD4+/CD8+ (P=0.012) and CD4+/CD3+ cells (P<0.001). Therefore, RBBP8 expression in patients with advanced gastric cancer is a prognostic marker that affects the proportion of CD4+ T-cell infiltration and may also be a biomarker for predicting ICI treatment response.
Journal • Checkpoint inhibition • IO biomarker
|
PD-L1 (Programmed death ligand 1) • CD8 (cluster of differentiation 8) • CD4 (CD4 Molecule) • RBBP8 (RB Binding Protein 8, Endonuclease)
7d
DAF-18/PTEN protects LIN-35/Rb from CLP-1/CAPN-mediated cleavage to promote starvation resistance. (PubMed, bioRxiv)
We conclude that the tumor suppressors DAF-18/PTEN and LIN-35/Rb function in a linear pathway, with LIN-35/Rb and the rest of the DREAM complex functioning as a transcriptional effector of DAF-18/PTEN protein-phosphatase activity resulting in repression of germline gene expression. This work is significant for revealing a network of tumor suppressors that promote survival during cellular and developmental quiescence.
Journal
|
PTEN (Phosphatase and tensin homolog) • RB1 (RB Transcriptional Corepressor 1) • HEXIM1 (HEXIM P-TEFb Complex Subunit 1)
10d
Targeting TUBG1 in RB1-negative tumors. (PubMed, FASEB J)
Subsequent investigations underscore L12's reduced neuronal axonal toxicity compared to vincristine. Lastly, L12 demonstrates promising results in inhibiting tumor growth in xenografted small cell lung cancer models, demonstrating potential specificity toward tumor cells while minimizing adverse effects on healthy tissues. This research emphasizes the potential of TUBG1 inhibitors as a promising advancement in personalized chemotherapy approaches and their potential as a groundbreaking treatment for various cancers.
Journal
|
RB1 (RB Transcriptional Corepressor 1) • CASP3 (Caspase 3) • E2F1 (E2F transcription factor 1)
|
vincristine
11d
A novel FTO-targeting nanodrug induces disulfidptosis and ameliorates the suppressive tumor immune environment to treat uveal melanoma. (PubMed, Biomaterials)
This study identifies FTO as a critical target for UM therapy and introduces SNAMA-apt as a promising nanodrug. The findings offer a foundation for m6A-targeted approaches in UM and other malignancies, addressing bioavailability, targeting, and immune evasion challenges.
Journal • PD(L)-1 Biomarker • IO biomarker
|
PD-L1 (Programmed death ligand 1) • GNAQ (G Protein Subunit Alpha Q) • BAP1 (BRCA1 Associated Protein 1) • GNA11 (G Protein Subunit Alpha 11) • SLC7A11 (Solute Carrier Family 7 Member 11) • FTO (Alpha-Ketoglutarate-Dependent Dioxygenase FTO)
11d
Corneal Fibropapilloma in Loggerhead Turtles (Caretta caretta) in Mediterranean Sea. (PubMed, Vet Med Sci)
This study provides the first research data on spirorchid-like parasite eggs and FP in loggerhead turtles (C. caretta) in the Mediterranean Sea in Türkiye.
Journal
|
VIM (Vimentin)
12d
Atlas of expression of acyl CoA binding protein/diazepam binding inhibitor (ACBP/DBI) in human and mouse. (PubMed, Cell Death Dis)
Furthermore, we identified multiple transcription factors that transactivate ACBP/DBI gene expression together with its coregulation network. Altogether, this study indicates the existence of conserved mechanisms determining the expression of ACBP/DBI in specific cell types of the mammalian organism.
Preclinical • Journal
|
TP53 (Tumor protein P53) • E2F1 (E2F transcription factor 1) • EGR1 (Early Growth Response 1)
12d
Intrathecal Chemotherapy for Central Nervous System Metastasis in Retinoblastoma (clinicaltrials.gov)
P=N/A, N=18, Recruiting, Eye & ENT Hospital of Fudan University | Trial primary completion date: May 2025 --> May 2028
Trial primary completion date
|
melphalan
12d
Neoadjuvant Radiotherapy for Malignant Lacrimal Sac Tumors (clinicaltrials.gov)
P=N/A, N=94, Recruiting, Eye & ENT Hospital of Fudan University | Trial primary completion date: Dec 2023 --> Dec 2028
Trial primary completion date
13d
Targeting NUDT21 SiRNA Drugs for Patients with Refractory Retinoblastoma (clinicaltrials.gov)
P1, N=20, Recruiting, Eye & ENT Hospital of Fudan University | Not yet recruiting --> Recruiting | Trial primary completion date: Jan 2025 --> May 2025
Enrollment open • Trial primary completion date
13d
Clinical and Proteomic Insights into a Cytokine Release Syndrome Triggered by Tebentafusp in a Metastatic Uveal Melanoma Patient: Case Report. (PubMed, J Clin Med)
A proteomic analysis tracked the cytokine changes from baseline to post-treatment, revealing significant elevations in inflammatory markers. These findings suggest potential strategies for more personalized CRS management in similar therapies.
Journal • IO biomarker
|
HLA-A (Major Histocompatibility Complex, Class I, A)
|
HLA-A*02:01
|
Kimmtrak (tebentafusp-tebn)
13d
Selective Up-Regulation of Tumor Suppressor Gene Retinoblastoma by Bisacridine Derivative Through Gene Promoter Quadruplex Structures for Cancer Treatment. (PubMed, Int J Mol Sci)
In comparison, A02 exhibited strong binding and destabilization to the RB promoter G-quadruplex only, which showed a much weaker effect than A06 on regulating RB expression and producing anti-tumor activity. As we know, this is the first study for up-regulating a tumor suppressor gene through destabilization of both the G-quadruplex and i-motif on the gene promoter, which provides a new strategy for innovative anti-cancer drug discovery and development.
Journal
|
RB1 (RB Transcriptional Corepressor 1)
13d
Retinocytoma: understanding pathogenesis, diagnosis, and treatment approaches. (PubMed, Int J Retina Vitreous)
The prognosis is generally favorable, with most patients maintaining good visual acuity and a low risk of progression to retinoblastoma. We aim to present an up-to-date review on epidemiology, clinical features, pathogenesis, macroscopic and histopathological features, diagnostic criteria, prognosis, and management strategies.
Review • Journal
|
RB1 (RB Transcriptional Corepressor 1)
13d
What is the predominant etiological factor for Merkel cell carcinoma in Turkey: viral infection or sun exposure? (PubMed, BMC Cancer)
The 9% incidence of gluteal localization in Turkish MCC cases, considering its geographical significance, is noteworthy. Notably, all MCC cases from Turkey in which microsatellite instability status has been assessed were found to be microsatellite stable. PRAME should be investigated in larger series for its potential role in the shared oncogenic pathways of MCC.
Journal • PD(L)-1 Biomarker • IO biomarker
|
PD-L1 (Programmed death ligand 1) • MSI (Microsatellite instability) • RB1 (RB Transcriptional Corepressor 1) • PRAME (Preferentially Expressed Antigen In Melanoma)
|
PD-L1 expression
13d
Chromosomal 3p loss and 8q gain drive vasculogenic mimicry via HIF-2α and VE-cadherin activation in uveal melanoma. (PubMed, Cell Death Differ)
Our results lead us to propose combining Belzutifan and FAKi as a personalized treatment strategy for UM patients. This approach inhibits VM formation and counters the initial hypoxic conditions resulting from chromosome 3p loss and chromosome 8q gain in UM patients, instilling confidence in the potential of this treatment strategy.
Journal
|
BAP1 (BRCA1 Associated Protein 1) • CTNNB1 (Catenin (cadherin-associated protein), beta 1) • EPAS1 (Endothelial PAS domain protein 1) • CDH5 (Cadherin 5) • PTK2 (Protein Tyrosine Kinase 2)
|
Welireg (belzutifan)
13d
Update on Retinoblastoma Predisposition and Surveillance Recommendations for Children. (PubMed, Clin Cancer Res)
Given the high penetrance of retinal tumors, we review the importance of close intraocular surveillance and consider recent data regarding surveillance for subsequent malignant neoplasms. Finally, we discuss the importance of counseling for survivors of intraocular disease to address risks of adult-onset tumors as well as to consider reproductive risks.
Journal
|
RB1 (RB Transcriptional Corepressor 1)
13d
Radiation Retinopathy: Microangiopathy-Inflammation-Neurodegeneration. (PubMed, Cells)
Although the gross anatomy of the retina does not seem to be affected by proton beam irradiation, the cellular composition and retinal function changed significantly in both WT and Cx3cr1 mice reflecting the clinical situation. Moreover, cataract formation was one of the major long-term effects of irradiation. We conclude that the murine model (WT and Cx3cr1 genotype) can be used to investigate proton-beam associated side effects in vivo as well as to test prospective interventions. Moreover, the loss of Cx3cr1 seems to be partially protective.
Journal
|
CX3CR1 (C-X3-C Motif Chemokine Receptor 1) • GFAP (Glial Fibrillary Acidic Protein)
14d
Functional-proteomics-based investigation of the cellular response to farnesyltransferase inhibition in lung cancer. (PubMed, iScience)
Additionally, we identified a synergistic drug combination involving tipifarnib and a ferroptosis inducer and discovered PTP4A1 as a regulator of interferon signaling. Our data, covering 15,080 proteins, offer valuable insights for future studies of farnesylation and FTIs.
Journal
|
NRAS (Neuroblastoma RAS viral oncogene homolog) • GNAQ (G Protein Subunit Alpha Q) • GNA11 (G Protein Subunit Alpha 11)
|
NRAS mutation
|
Zarnestra (tipifarnib)
15d
KAT8 facilitates the proliferation of cancer cells through enhancing E7 function in HPV-associated cervical cancer. (PubMed, Acta Biochim Biophys Sin (Shanghai))
This study also demonstrates that KAT8 is essential for the acetylation of E7 and plays a critical role in facilitating the interaction between pRb/E2F1 and E7 in cervical cancer cells. In conclusion, these results highlight KAT8 as a key driver of cervical cancer progression, promoting the expression of HPV E7 and its associated oncogenic signaling pathways.
Journal
|
E2F1 (E2F transcription factor 1)
15d
Retinoblastoma Phase II Expanded Access Clinical Trial (clinicaltrials.gov)
P2, N=30, Recruiting, Targeted Therapy Technologies, LLC | Not yet recruiting --> Recruiting | Initiation date: Nov 2024 --> Feb 2025
Enrollment open • Trial initiation date
|
topotecan • topotecan episcleral
15d
Rare Lacrimal Gland Melanoma: A Case Report and Treatment Insights. (PubMed, Am J Case Rep)
Subsequent progression required treatment with ipilimumab and nivolumab, which resulted in near complete regression of the orbital tumor. CONCLUSIONS This case report highlights the diagnostic challenge in distinguishing between melanoma of known and unknown primary origins. It emphasizes the importance of thorough histological work-up and heightened suspicion for melanoma of the lacrimal gland, despite its rarity, to ensure prompt diagnosis and treatment due to its metastatic potential.
Journal
|
PD-L1 (Programmed death ligand 1) • LAG3 (Lymphocyte Activating 3)
|
Opdivo (nivolumab) • Yervoy (ipilimumab)
17d
Baseline retinoblastoma transcriptional corepressor 1 (Rb1) functional inactivation is a pre-requisite but not sufficient for small-cell histological transformation in epidermal growth factor receptor (EGFR) mutant lung adenocarcinomas post-tyrosine kinase inhibitor therapy. (PubMed, Virchows Arch)
Except for TP53 and PTEN, recurrent mutations in other common oncogenes tested were not detected at baseline or at progression. Within the limitation of a small sample size, specific molecular events that drive small-cell transformation remain unclear.
Journal
|
EGFR (Epidermal growth factor receptor) • TP53 (Tumor protein P53) • PTEN (Phosphatase and tensin homolog) • RB1 (RB Transcriptional Corepressor 1) • CCND1 (Cyclin D1)
|
TP53 mutation • EGFR mutation
19d
Identification of lncRNA-miRNA-mRNA ceRNA axes and KEGG pathways related to uveal melanoma metastasis. (PubMed, Technol Health Care)
The results showed that the involvement of UM-related Wnt/β-catenin and Chemokine signaling pathways and the ceRNA regulatory axes showed noteworthy interest in UM metastasis.
Journal
|
H19 (H19 Imprinted Maternally Expressed Transcript) • PVT1 (Pvt1 Oncogene) • MAP3K7 (Mitogen-Activated Protein Kinase Kinase Kinase 7) • MIR106B (MicroRNA 106b) • MIR122 (MicroRNA 122) • MIR6836 (MicroRNA 6836) • PLCB4 (Phospholipase C Beta 4) • WNT7B (Wnt Family Member 7B) • MAPK10 (Mitogen-Activated Protein Kinase 10)
19d
KRASG12D-driven pentose phosphate pathway remodeling imparts a targetable vulnerability synergizing with MRTX1133 for durable remissions in PDAC. (PubMed, Cell Rep Med)
This system enhances the efficacy of PGG and MRTX1133, achieving durable remissions (85% overall response rate) and long-term survival (100% progression-free survival) in patient-derived xenografts and spontaneous PDAC mice. This study reveals the role of KRASG12D-preferred PPP reprogramming in MRTX1133 resistance and proposes a potentially therapeutic strategy for KRASG12D-mutated PDAC.
Journal
|
KRAS (KRAS proto-oncogene GTPase) • E2F1 (E2F transcription factor 1)
|
KRAS mutation • KRAS G12D • KRAS G12
|
MRTX1133
21d
Enrollment open
|
roginolisib (IOA-244)
21d
The LINC01315-encoded small protein YAPer-ORF competes with PRP4k to hijack YAP signaling to aberrantly promote cell growth. (PubMed, Cell Death Differ)
Moreover, treatment with an anti-YAPer-ORF neutralizing antibody effectively suppressed uveal melanoma growth, highlighting the therapeutic potential of targeting YAPer-ORF. These findings collectively establish YAPer-ORF as a critical regulator of YAP activity, further highlighting the disruption of YAPer-ORF activity as a potential therapeutic strategy against YAP-driven human cancers and developmental diseases.
Journal
|
GNAQ (G Protein Subunit Alpha Q) • CCND1 (Cyclin D1)
25d
Prognostic significance of pigmentation and stem cell markers in Indian population of uveal melanoma. (PubMed, Br J Ophthalmol)
Our study highlights the association between PAX3 expression, pigmentation markers such as MITF and TRYP2 and cancer stem-cell markers in UM progression.
Journal
|
ABCG2 (ATP Binding Cassette Subfamily G Member 2) • DCT (Dopachrome Tautomerase) • MITF (Melanocyte Inducing Transcription Factor) • PRSS1 (Serine Protease 1) • PAX3 (Paired Box 3)
25d
Poly(amino acid) nanoformulation of cyclin-dependent kinase 4 and 6 inhibitor for molecularly targeted immunotherapy in triple-negative breast cancer. (PubMed, J Control Release)
To address this challenge, three pH- and glutathione-responsive poly(amino acid) nanogels composed of methoxy poly(ethylene glycol) of various lengths and poly(L-glutamic acid-co-L-cystine) (mPEG-P(Glu10-co-Cys25)) were developed to efficiently deliver the CDK4/6i abemaciclib (ABE) to TNBC cells...Furthermore, NG2000/ABE enhanced immune checkpoint therapy for TNBC, achieving a tumor inhibition rate of 89.66 %. These findings demonstrate the potential of poly(amino acid) nanoformulations for delivering CDK4/6 inhibitors as molecularly targeted immunotherapy for TNBC in clinical applications.
Journal
|
CDK4 (Cyclin-dependent kinase 4)
|
Verzenio (abemaciclib)
25d
Anticancer activity of thymoquinone in non-small cell lung cancer and possible involvement of PPAR-γ pathway. (PubMed, Int J Radiat Biol)
Thymoquinone (TQ) is an ingredient of Nigella sativa and Cisplatin (CDDP) is the most active chemotherapeutic agent in lung cancer...As a result, combined therapy of TQ, CDDP, and IR have been shown to increase apoptosis by sensitizing NSCLC cells to IR. These in vitro results are the basis because they demonstrate that it may be useful to include TQ in combined NSCLC cell treatments to reduce tumor progression.
Journal • IO biomarker
|
TP53 (Tumor protein P53) • BCL2 (B-cell CLL/lymphoma 2) • CCND1 (Cyclin D1) • TNFA (Tumor Necrosis Factor-Alpha) • CASP8 (Caspase 8) • CASP9 (Caspase 9) • PPARG (Peroxisome Proliferator Activated Receptor Gamma) • ANXA5 (Annexin A5) • PPARA (Peroxisome Proliferator Activated Receptor Alpha) • RELA (RELA Proto-Oncogene)
|
cisplatin
26d
CDK6-Dependent, CDK4-Independent Synovial Hyperplasia in Arthritic Mice and Tumor Necrosis Factor-α-Induced Proliferation of Synovial Fibroblasts. (PubMed, Int J Mol Sci)
Palbociclib, a dual CDK4/6 kinase inhibitor used for breast cancer, has been explored as a treatment option for rheumatoid arthritis (RA)...Notably, synovial hyperplasia was not observed in Cdk6-deficient mice. CIA-synovial hyperplasia depends on CDK6, but not CDK4, expression.
Preclinical • Journal
|
CDK4 (Cyclin-dependent kinase 4) • TNFA (Tumor Necrosis Factor-Alpha) • CDK6 (Cyclin-dependent kinase 6) • SAA1 (Serum Amyloid A1) • SAAL1 (Serum Amyloid A Like 1)
|
Ibrance (palbociclib)
26d
Enrollment open
|
KIT (KIT proto-oncogene, receptor tyrosine kinase)
|
NN3201
27d
Dynamic Contrast-Enhanced Magnetic Resonance Imaging Findings and the Relevance of Histopathological Findings in Intraocular Solitary Fibrous Tumors. (PubMed, Cureus)
DCE MRI revealed two patterns of time-intensity curves (TICs): marked enhancement and washout in T2-hyperintense areas and persistent enhancement in T2-hypointense areas. The intensity of T2-weighted imaging, enhancement pattern, and type of TICs in this case may be specific to intraocular SFT. An integrated evaluation of these findings may help differentiate SFT from other intraocular tumors.
Journal
|
STAT6 (Signal transducer and activator of transcription 6)
27d
Transarterial Chemoembolization for the Treatment of Uveal Melanoma With Liver Metastases (clinicaltrials.gov)
P2, N=28, Active, not recruiting, Thomas Jefferson University | Recruiting --> Active, not recruiting
Enrollment closed
|
carmustine
27d
METTL14-mediated m6A modification of LINC00340 exerts oncogenic role in retinoblastoma by regulating Notch signaling pathway. (PubMed, Int Ophthalmol)
The findings of study reveal that METTL14-mediated m6A modification of LINC00340 exerts oncogenic function in RB via Notch signaling pathway, which may uncover a novel molecular mechanism driving RB progression and identify a potential therapeutic target for RB.
Journal
|
METTL14 (Methyltransferase 14)
|
dactinomycin
27d
STARLING: A Study of TBio-4101 (TIL) and Pembrolizumab in Patients With Advanced Solid Tumors (clinicaltrials.gov)
P1, N=31, Terminated, Turnstone Biologics, Corp. | Recruiting --> Terminated | N=60 --> 31 | Trial completion date: Jun 2025 --> Feb 2025; Sponsor decision
Enrollment change • Trial completion date • Trial termination
|
Keytruda (pembrolizumab) • cyclophosphamide • oxaliplatin • irinotecan • fludarabine IV • TIDAL-01
27d
Neoadjuvant Tebentafusp for Uveal Melanoma (clinicaltrials.gov)
P2, N=19, Not yet recruiting, Thomas Jefferson University | Trial completion date: Apr 2029 --> Jul 2029 | Initiation date: Jan 2025 --> Apr 2025 | Trial primary completion date: Oct 2025 --> Jan 2026
Trial completion date • Trial initiation date • Trial primary completion date
|
Kimmtrak (tebentafusp-tebn)
27d
Tebentafusp-tebn With LDT in Metastatic UM (clinicaltrials.gov)
P1/2, N=109, Not yet recruiting, Thomas Jefferson University | Trial completion date: Aug 2026 --> Feb 2027 | Initiation date: Oct 2024 --> Apr 2025 | Trial primary completion date: Jul 2026 --> Jan 2027
Trial completion date • Trial initiation date • Trial primary completion date
|
carmustine • Kimmtrak (tebentafusp-tebn) • Leukine (sargramostim)